Fate Therapeutics Inc (NAS:FATE)
$ 3.755 0.095 (2.6%) Market Cap: 427.44 Mil Enterprise Value: 138.57 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 58/100

Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 04:00PM GMT
Release Date Price: $40.95 (+3.54%)
Michael Schmidt
Guggenheim Securities, LLC - Analyst

All right. Good morning and welcome. My name is Michael Schmidt. I am a senior biotech analyst with Guggenheim Securities. And it's my great pleasure to welcome Fate Therapeutics. With us today, we have Scott Wolchko, President and CEO; as well as Ed Dulac, CFO. Welcome guys, and thanks for joining us today.

Scott Wolchko
Fate Therapeutics, Inc. - President & CEO

Welcome. Thank you for having us.

Ed Dulac
Fate Therapeutics, Inc. - CFO

Welcome, Michael.

Questions & Answers

Michael Schmidt
Guggenheim Securities, LLC - Analyst

I think most of the investors are pretty familiar with Fate which has obviously been one of the pioneers in the iPSC-derived cell therapy field with several programs now in clinical development. So I thought it'd probably be most helpful to jump right into some of your clinical programs, perhaps, starting with FT516 where we have seen data most recently at ASH, an update on your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot